arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

GERON CORP

GERN
$1.48 ▼ -0.08 (-5.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bearish
auto_awesome

Analytical Summary

GERON CORP faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 30.9%
Op. Margin 0.3%
ROIC 0.0%
FCF / Share $-93.98
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.52
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.84M
↑ +30.9%
Net Income Profit after all expenses
$-3.64M
↑ +81.6%
Operating Margin Operating profit as % of sales
0.3%
↑ +101.0%
FCF / Share Free cash flow per share
$-93.98
↓ -130331.9%
Long-Term Debt Long-term obligations
$119.83M
— +0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
20
Financial Health
42
Cash Quality
76

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters